Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
European Journal of Cancer2018Vol. 107, pp. 142–152
Citations Over TimeTop 10% of 2018 papers
Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno, James Good, Jérôme Fayette, Nathaniel Bouganim, Neal Ready, Paul Clement, Caroline Even, Raymond Jang, Stuart J. Wong, Ulrich Keilholz, Jill Gilbert, Moon J. Fenton, Irene Braña, Stéphanie Henry, Éva Remenár, Zsuzsanna Pápai, Lillian L. Siu, Anthony Jarkowski, J. Armstrong, Kobby Asubonteng, Jean Fan, Giovanni Melillo, Ricard Mesı́a
Abstract
Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first- and second-line settings. In an ad hoc analysis, HPV-positive patients had a numerically higher response rate and survival than HPV-negative patients.
Related Papers
- → Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status(2015)19 cited
- → Durvalumab (Imfinzi™)(2017)4 cited
- → Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer(2020)2 cited
- → Durvalumab for the treatment of PD-L1 non-small cell lung cancer(2020)1 cited
- → P21.09 Does Duration of Maintenance Durvalumab Matter? Relationship between Length of Durvalumab Therapy and PFS.(2021)